Sai Parenteral’s IPO 2026: Date, Price Band ₹372–₹392, GMP & Allotment

By /
Sai Parenteral's IPO
SP
Sai Parenteral’s Limited IPO
Pharmaceutical Formulations · CDMO · Branded Generics · Injectables
📋 Mainline IPO Fresh + OFS NSE, BSE
₹392
Upper Price
₹408.79 Cr
Issue Size
Apr 2, 2026
Listing Date
₹1,731.83 Cr
Market Cap (Pre)
📅 IPO Timetable
All dates tentative
🟢
IPO Opens
Tuesday, 24 March 2026
Bidding starts — apply before close
🔒
IPO Closes
Friday, 27 March 2026
Last day to bid — closes at 5:00 PM IST
📊
Basis of Allotment
Monday, 30 March 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Wednesday, 1 April 2026
Unallotted funds returned; shares credited to demat
🏷️
Thursday, 2 April 2026
Trading begins from 10:00 AM IST
📋 IPO Details
IPO Open Date24 March 2026 (Tue)
IPO Close Date27 March 2026 (Fri)
Listing Date2 April 2026 (Thu)
Face Value₹5 per share
Price Band₹372 to ₹392
Issue Price (Upper)₹392 per share
Issue TypeBook Build — Fresh + OFS
Lot Size38 shares
Total Issue Size1,04,28,288 shares (₹408.79 Cr)
Fresh Issue72,70,408 shares (₹285 Cr)
Offer for Sale (OFS)31,57,880 shares (₹123.79 Cr)
Promoter Holding (Pre)61.23%
Pre-Issue Shares3,69,08,823
Post-Issue Shares4,41,79,231
Market Cap (Pre-IPO)₹1,731.83 Cr
Listing ExchangeBSE, NSE
Lead ManagerArihant Capital Markets Ltd.
RegistrarBigshare Services Pvt.Ltd.
💰 Lot Size & Minimum Investment
At upper price ₹392
Investor TypeLotsSharesAmount
Retail — Minimum138₹14,896
Retail — Maximum13494₹1,93,648
S-HNI (sNII) — Min14532₹2,08,544
S-HNI (sNII) — Max672,546₹9,98,032
B-HNI (bNII) — Min682,584₹10,12,928
⚠️ Note: Investors can bid for a minimum of 38 shares and in multiples thereof. Retail maximum application is up to ₹2,00,000.
👥 Investor Reservation
Allocated portion of Net Offer
Not more than 50%
QIB Portion
Not less than 35%
Retail Portion
Not less than 15%
NII Portion
📊 Subscription Status
Loading…
📈 Company Financials
Restated Consolidated · ₹ Crore
Metric30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Assets376.24272.39268.10133.96
Total Income89.43163.74155.1897.03
PAT7.7614.438.424.38
EBITDA16.2439.4431.7017.64
Net Worth209.3795.7876.4031.49
Total Borrowing76.0793.95118.7968.55
Income Growth
FY 2022–23₹97.03 Cr
FY 2023–24₹155.18 Cr
FY 2024–25₹163.74 Cr
H1 FY26 (Apr–Sep 2025)₹89.43 Cr
🎯 Key Performance Indicators
16.82%
ROE
FY 2024–25
28.92%
ROCE
FY 2024–25
8.88%
PAT Margin
FY 2024–25
24.18%
EBITDA Margin
FY 2024–25
5.13%
ROE (H1)
Sep 30, 2025
9.28%
ROCE (H1)
Sep 30, 2025
8.93%
PAT Margin (H1)
Sep 30, 2025
10.89x
Price/Book
Sep 30, 2025
⚖️ Valuation & EPS
Pre-IPO EPS
₹5.43
FY25 earnings + pre-issue shares
P/E: 72.19x
Post-IPO EPS
TBD
Post-issue shares dilution
Price to Book Value
10.89x
At ₹392 (post-issue book)
Market Cap (Pre-IPO)
₹1,731.83 Cr
At issue price ₹392
ℹ️ Pre-IPO EPS (₹5.43) based on pre-issue shares (3,69,08,823) and FY25 earnings. Post-IPO EPS calculated based on post-issue shares (4,41,79,231) and annualized H1 FY26 earnings.
🎯 Objects of the Issue
Net proceeds utilisation
1
Capacity expansion and upgradation of manufacturing facilities
₹110.80 Cr
2
Proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) via Singapore subsidiary
₹35.64 Cr
3
Working capital requirements of the Company
₹33.00 Cr
4
Establishment of a new R&D Centre
₹18.02 Cr
Total Strategic Allocation ₹211.76 Cr
🏢 About Sai Parenteral’s Limited
Est. 2001 · Hyderabad · Pharmaceuticals

Incorporated in 2001, Sai Parenteral’s Limited is a diversified pharmaceutical formulations company with deep expertise in R&D and manufacturing. The company operates in two distinct segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services.

Its extensive portfolio covers chronic therapeutic areas like cardiovascular, anti-diabetic, and respiratory health, offered via dosage forms such as injectables and tablets. With five manufacturing facilities across Hyderabad and Ongole, and a growing export presence in markets like Australia and Southeast Asia, Sai Parenteral’s serves both government agencies and private healthcare providers globally.

Therapeutic Segments
💊
Chronic Care
Cardiovascular, Neuropsychiatry, and Anti-Diabetic formulations
🔬
CDMO Services
Specialized manufacturing for domestic and international pharma partners
🏭
Manufacturing
5 units with WHO-GMP and TGA-Australia accreditations
🌍
Global Presence
Exports to Australia, New Zealand, and regulated markets in Africa
Competitive Strengths
✅Established track record as a diversified generic formulations player
🌐Strategically located, accredited manufacturing facilities (WHO-GMP, TGA)
📈Proven history of value-accretive international acquisitions
👨‍⚕️Experienced promoters with deep domain knowledge in pharmaceuticals
Company Promoters
AK
Anil Kumar Karusala
Promoter, Sai Parenteral’s Limited
VG
Vijitha Gorrepati
Promoter, Sai Parenteral’s Limited
📅 Key Dates
IPO Opens24 Mar 2026
IPO Closes27 Mar 2026
Allotment30 Mar 2026
Refund & Share Credit1 Apr 2026
Listing Day2 Apr 2026
💡 Quick Summary
Price Band₹372 – ₹392
Issue Price₹392 / share
Lot Size38 shares
Min. Investment (Retail)₹14,896
Issue Size₹408.79 Cr
ListingBSE, NSE
🏦 Registrar & Lead Manager
Registrar
Bigshare Services Pvt.Ltd.
📞 +91-22-6263 8200
[email protected]
Lead Manager
Arihant Capital Markets Ltd.
📍 Registered Address
Sai Parenteral’s Ltd.
Lavanya Arcade Jayabheri Enclave,
Gachibowli, Hyderabad,
Telangana — 500032
📞 +91 79979 91301
[email protected]
🛡️ Regulatory Note: Mainline IPO investments are subject to SEBI regulations. Always read the Prospectus/RHP before applying. Consult a SEBI-registered advisor before investing.
⚠️ Disclaimer: This page presents publicly available information from the Sai Parenteral’s IPO RHP for informational purposes only. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Sai Parenteral’s IPO 2026: Date, Price Band ₹372–₹392, GMP & Allotment GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top